Gonadotropin levels and secretory patterns in patients with typical and atypical polycystic ovarian disease.
Gonadotropin levels and secretory patterns were studied in 28 oligomenorrheic patients with various types of polycystic ovary disease (PCO). On the basis of ovarian morphology and histology, the patients PCOuld be separated into two distinct categories arbitarily designated "typical" (type I) and "atypical" (type II) PCO. Although no differences were noted in symptomatology or 17-ketosteroid, testosterone, or follicle-stimulating hormone levels, the 12 type I patients demonstrated widely fluctuating, but markedly elevated, luteinizing hormone (LH) levels, while the 16 type II patients demonstrated lower and less fluctuating LH levels which were comparable to those found during the normal follicular phase. It is likely that type I PCO is a distinct entity similar to that described by Stein and Leventhal, while type II co represents a heterogenous spectrum of disorders, many of which remain obscure.
D015065:17-Hydroxycorticosteroids / Q000652:urine; D015068:17-Ketosteroids / Q000652:urine; D000293:Adolescent; D000328:Adult; D000858:Anovulation / Q000209:etiology / Q000378:metabolism; D003907:Dexamethasone / Q000008:administration & dosage / Q000627:therapeutic use; D005246:Feedback; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D006062:Gonadotropins / Q000378:metabolism*; D006801:Humans; D006965:Hyperplasia; D008184:Luteal Cells / Q000473:pathology; D007986:Luteinizing Hormone / Q000097:blood; D009839:Oligomenorrhea / Q000378:metabolism; D010048:Ovarian Cysts / Q000145:classification / Q000378:metabolism*; D010049:Ovarian Diseases / Q000188:drug therapy / Q000378:metabolism*; D010053:Ovary / Q000473:pathology; D013739:Testosterone / Q000009:adverse effects / Q000097:blood
D015065:17-Hydroxycorticosteroids; D015068:17-Ketosteroids; D006062:Gonadotropins; D013739:Testosterone; D003907:Dexamethasone; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone